Novo Nordisk's oral semaglutide (Wegovy pill) shows greater weight loss than injections in real-world data: what does it mean for Canadian GLP-1 patients?

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

A real-world observational study, reported by Reuters on September 30, 2026, found that patients who switched from injectable semaglutide (sold in Canada as Wegovy for obesity and Ozempic for type 2 diabetes, both by Novo Nordisk) to the company's oral semaglutide pill lost more weight than those who continued with the subcutaneous injection. The study did not come from a randomized controlled trial, and the full dataset has not yet been published in a peer-reviewed journal, so the findings carry the usual caveats of observational, industry-adjacent research. Still, the signal is notable enough that Canadian clinicians and patients on GLP-1 therapy are asking the same question: when, and whether, an oral option will be available here.

For Canadians already on injectable semaglutide, the short answer is: not yet. Health Canada has approved subcutaneous semaglutide 2.4 mg (Wegovy) for chronic weight management in adults with obesity or overweight plus at least one weight-related condition, and semaglutide 1 mg (Ozempic) for type 2 diabetes. The oral formulation of semaglutide (brand name Rybelsus in its lower-dose diabetes version) is approved by Health Canada only for type 2 diabetes at doses up to 14 mg, not for obesity or weight management. A higher-dose oral semaglutide specifically for weight loss has received FDA approval in the United States, but Health Canada has not issued a comparable approval as of October 1, 2026. Canadian patients cannot legally obtain the higher-dose oral weight-loss pill through a standard Canadian pharmacy at this time.

What this means in Canada

The regulatory gap matters practically. Injectable Wegovy is listed on some provincial formularies, but coverage is uneven. In Ontario, OHIP does not cover Wegovy; patients pay out of pocket or rely on private insurance, with monthly costs running roughly CAD $350 to $500 depending on pharmacy and dose. In Quebec, the Régie de l'assurance maladie du Québec (RAMQ) does not list Wegovy on its public formulary for obesity as of this writing. British Columbia's PharmaCare and Alberta's Alberta Health Care Insurance Plan (AHCIP) similarly do not provide broad public coverage for semaglutide for weight management, though coverage for Ozempic in the context of type 2 diabetes is more widely available across provinces. The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a specific position statement on GLP-1 agonists for weight management as of October 2026. The Obesity Canada clinical practice guidelines, updated in 2020 and referenced by many Canadian prescribers, support pharmacotherapy for obesity as part of a comprehensive treatment plan, but predate the current generation of high-dose GLP-1 data.

For the oral pill specifically, Health Canada has not yet issued guidance on a high-dose oral semaglutide indication for obesity. If Novo Nordisk files a submission, the review process typically takes 12 to 18 months under standard review, or potentially less under priority review if the agency grants that designation. There is no public indication yet that a submission has been filed with Health Canada for this specific indication.

What changed

GLP-1 receptor agonists are a class of medications that mimic the hormone glucagon-like peptide-1, which the gut releases after eating. They slow gastric emptying, reduce appetite, and act on brain regions that regulate food intake. Semaglutide is one such drug. The injectable version at 2.4 mg weekly (Wegovy) produced roughly 15 percent average body weight loss in the pivotal STEP 1 trial published in the New England Journal of Medicine in 2021, a result that shifted how obesity medicine practitioners think about pharmacotherapy.

The oral formulation is a different technical challenge. Peptide drugs are normally broken down in the stomach before they can be absorbed. Novo Nordisk solved this partly by co-formulating semaglutide with an absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate). The lower-dose oral version (Rybelsus, 7 to 14 mg) is already approved in Canada for type 2 diabetes and produces modest weight loss as a secondary effect. The higher-dose oral formulation studied for obesity is a different product at a higher dose, and the real-world data reported by Reuters suggest it may produce weight loss comparable to or greater than the injection in patients who switch.

Why might the pill outperform the shot in a real-world setting? Researchers have proposed a few mechanisms: daily oral dosing may produce a more consistent drug exposure profile than a once-weekly injection, and patients who struggled with injection-site reactions or needle aversion may adhere better to a pill. These are hypotheses, not confirmed findings from the current dataset.

What Canadian patients should know

If you are currently on injectable semaglutide (Wegovy or Ozempic) in Canada, there is no approved oral alternative for weight management to switch to at this time. Do not attempt to use the diabetes-dose oral semaglutide (Rybelsus) at higher-than-approved doses; the formulation, absorption characteristics, and safety data differ from the obesity-indication product studied in the new data.

If you are interested in GLP-1 therapy for weight management and have not yet started, injectable Wegovy is the currently approved option in Canada. Some Canadian telehealth platforms, including Felix (a Canadian men's and primary-care health platform) and Maple (a Canadian virtual care platform), can connect patients with prescribers who assess eligibility for Wegovy. Science & Humans (scienceandhumans.com), a Canadian hormone and metabolic health platform, also lists GLP-1 assessment among its services. Cleo and Phoenix operate in the Canadian women's health and men's health space respectively and may offer obesity medicine consultations. US-only platforms such as Hone Health, Midi, and Winona do not serve Canadian patients and cannot prescribe medications valid at Canadian pharmacies.

Coverage varies significantly by province. If cost is a barrier, ask your prescriber whether you qualify for Novo Nordisk's patient support program (called Wegovy Together in Canada), which may reduce out-of-pocket costs for eligible patients.

Limitations and open questions

The Reuters report does not specify the study's sample size, follow-up duration, or whether it was sponsored by Novo Nordisk. Observational studies of patients who switch medications are prone to selection bias: people who switch may be more motivated, may have had better initial responses, or may differ from non-switchers in ways the analysis did not fully control for. Without peer review and full data transparency, the magnitude of the weight-loss difference between pill and injection cannot be taken as settled.

Health Canada has not commented on a timeline for reviewing a high-dose oral semaglutide obesity indication. The SOGC has not issued a position on GLP-1 agonists for weight management in the context of hormonal health, including perimenopause or menopause, where weight gain is a common concern and where some clinicians are beginning to consider GLP-1 therapy alongside hormone therapy. That intersection remains an open research question. Long-term cardiovascular outcome data for the higher-dose oral formulation in obesity are not yet available in the way they are for the injectable version (the SELECT trial, published in 2023, showed cardiovascular benefit for injectable semaglutide 2.4 mg).

Canadian patients and prescribers should watch for Health Canada communications and any Canadian formulary updates. The Canadian Institutes of Health Research (CIHR) has funded obesity pharmacotherapy research, but no Canadian-specific trial on oral high-dose semaglutide has been announced publicly as of this date.

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.